Related Experiment Videos
Phosphorylation of HDM2 by Akt
Margaret Ashcroft1, Robert L Ludwig, Douglas B Woods
1CRC, Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK. ashcroft@icr.ac.uk
Oncogene
|April 18, 2002
Summary
The serine-threonine kinase Akt phosphorylates HDM2 (human double minute 2) protein, impacting tumor suppressor p53 regulation. This Akt-HDM2 interaction enhances HDM2 expression and nuclear localization, crucial for cell proliferation and stress responses.
Area of Science:
- Molecular Biology
- Cellular Signaling
- Cancer Research
Background:
- The HDM2 (human double minute 2) protein is a critical regulator of the tumor suppressor p53.
- HDM2 function is vital for controlling cell proliferation and cellular stress responses.
- Post-translational modifications of HDM2 are increasingly recognized as key regulators of its cellular activity.
Purpose of the Study:
- To investigate the regulatory mechanisms controlling HDM2 function.
- To explore the association between HDM2 and the serine-threonine kinase Akt.
- To elucidate the role of Akt in modulating HDM2 expression and localization.
Main Methods:
- Co-immunoprecipitation assays to detect HDM2-Akt association.
- Western blotting to assess protein levels and phosphorylation status.
- Analysis of mutated HDM2 proteins and treatment with PI3 kinase inhibitors.
Main Results:
- HDM2 associates with Akt upon growth factor stimulation in human primary cells.
- Akt phosphorylation (Ser 473) correlates with increased HDM2 expression and nuclear localization.
- Mutations at Akt consensus sites (Ser 166, 186) did not fully account for increased HDM2 expression, which was sensitive to PI3 kinase inhibition.
- Evidence for an additional Akt phosphorylation site on HDM2 was identified.
Conclusions:
- Akt signaling pathway plays a significant role in regulating HDM2 protein levels and localization.
- Akt-mediated phosphorylation of HDM2 is a key mechanism influencing p53 pathway activity.
- These findings reveal a novel regulatory loop involving Akt and HDM2, with implications for cancer therapy targeting the p53 pathway.